<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kalpana Manthiram, MD, MSCI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><strong>P</strong>eriodic <strong>f</strong>ever, <strong>a</strong>phthous stomatitis, <strong>p</strong>haryngitis, and <strong>a</strong>denitis (PFAPA) syndrome is a recurrent or periodic fever syndrome [<a href="#rid1">1-5</a>]. The periodic fever syndromes are autoinflammatory diseases characterized by attacks of seemingly unprovoked inflammation and are distinguished from autoimmune disorders by the lack of significant levels of either autoantibodies or autoreactive T cells [<a href="#rid6">6</a>]. These syndromes are due to defects in proteins involved in the innate immune system [<a href="#rid7">7</a>]. Some periodic fevers syndromes are caused by pathogenic variants in single genes and are therefore considered to have monogenic inheritance. However, most patients with recurrent fever syndromes do not have pathogenic variants identified in a single gene and are likely complex genetic diseases [<a href="#rid8">8,9</a>]. PFAPA is the most common diagnosis among these patients.</p><p>This topic reviews the pathogenesis, clinical manifestations, diagnosis, and treatment of PFAPA. An overview of the periodic fevers and other autoinflammatory diseases is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p>The pediatrician is generally the first clinician to evaluate the child with recurrent fever since these disorders often become clinically apparent in childhood. Patients with recurrent fever have intermittent episodes of fever separated by afebrile intervals. This type of fever pattern is distinct from prolonged fever or fever of unknown origin in which a single illness leads to a protracted, continuous or near continuous period of fever. The approach to children with these fever patterns is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/5996.html" rel="external">"Fever of unknown origin in children: Etiology"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PFAPA is the most common periodic fever syndrome. It generally begins between one and four years of age [<a href="#rid5">5,10,11</a>], although a younger median age of onset (11 months) was seen in a smaller Norwegian cohort [<a href="#rid12">12</a>]. Case series have been reported in a variety of ethnic and racial groups in the United States, East Asia, the Middle East, and South America [<a href="#rid2">2,3,13-15</a>]. However, a study in Israel found that patients with PFAPA were more likely to be of Mediterranean descent (Sephardic Jews and Israeli Arabs) than children presenting to the same hospital with asthma [<a href="#rid16">16</a>]. Additional studies in other countries are needed to further understand ethnic predispositions to the syndrome.</p><p>Attacks typically cease by 10 years of age in most patients. However, a minority of patients continue to have episodes into adulthood, and others have onset of fever episodes in adulthood [<a href="#rid4">4,17</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Data suggest that PFAPA is caused by polygenic or complex inheritance of pathogenic variants in many genes in association with environmental factors [<a href="#rid5">5,9</a>]. Several studies suggest that a portion of PFAPA cases are familial [<a href="#rid13">13,17-21</a>], and most familial cases exhibit autosomal-dominant inheritance [<a href="#rid22">22,23</a>]. In a study of two European-American cohorts and one Turkish cohort, several common genetic mutations in noncoding regions of the genome that are associated with recurrent aphthous ulcers and Behçet syndrome were also found to be strongly associated with PFAPA syndrome [<a href="#rid9">9</a>]. These identified risk variants are near the interleukin (IL) 12A (<em>IL12A</em>), signal transducer and activator of transcription 4 (<em>STAT4</em>), <em>IL10</em>, and C-C motif chemokine receptor 1-C-C motif chemokine receptor 3 (<em>CCR1-CCR3</em>) genes and lead to elevated IL-12 production, elevated <em>STAT4</em> expression, decreased IL-10 production, and decreased <em>CCR1</em> expression, respectively [<a href="#rid9">9,24,25</a>]. In aggregate, these variants implicate heightened antigen-presenting cell and CD4+ T cell activation in the pathogenesis of PFAPA. Consistent with this finding, during flares, PFAPA patients have elevated levels of several inflammatory cytokines involved in myeloid cell and CD4+ T cell activation including interferon (IFN) gamma, tumor necrosis factor (TNF) alpha, IL-6, IL-18 [<a href="#rid26">26-28</a>], and IFN-gamma-induced proteins including IFN-gamma-induced protein 10 (IP10, also called CXCL10 for chemokine, CXC motif, ligand 10) and monokine induced by gamma interferon (MIG or CXCL9) [<a href="#rid28">28,29</a>].</p><p>These results also indicate that PFAPA, Behçet syndrome, and recurrent aphthous stomatitis have genetic similarities and, therefore, share features of their pathogenesis. Some have proposed grouping these disorders into a disease family called Behçet spectrum disorders (BSD) [<a href="#rid9">9</a>]. Among the BSDs, recurrent aphthous stomatitis is mildest, Behçet syndrome is most severe, and PFAPA is intermediate. Persons with vaginal ulcers during regular fever flares, thereby exhibiting features of both PFAPA and Behçet syndrome, have been reported [<a href="#rid9">9,30,31</a>].</p><p>Several class I and class II<em> </em>human leukocyte antigen (HLA) alleles are also significantly associated with PFAPA [<a href="#rid9">9</a>]. Most of these alleles are distinct from those identified for Behçet syndrome and recurrent aphthous ulcers. However, HLA-B15 was identified as a risk allele for all of the BSDs.</p><p>Genomic analyses of familial cases by genome-wide linkage analysis and whole-exome sequencing have not revealed rare variants in a single, common gene for PFAPA [<a href="#rid22">22</a>].</p><p>Most patients with PFAPA do not have mutations in genes previously implicated in monogenic periodic fever syndrome such as familial Mediterranean fever gene (<em>MEFV</em>)<em>, </em>mevalonate kinase (<em>MVK</em>)<em>, </em>TNF receptor superfamily member 1A (<em>TNFRSF1A</em>), or NLR family pyrin domain-containing 3 (<em>NLRP3</em>). It is possible that variants in these genes modify the clinical presentation of PFAPA, particularly in populations with a high prevalence of <em>MEFV</em> variants. Carriers of<em> MEFV</em> mutations with a clinical diagnosis of PFAPA were found to have earlier age of onset, shorter and more irregular episodes, and lower likelihood of fully responding to tonsillectomy; however, these results have not been replicated in independent cohorts [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'MEFV gene mutations'</a>.)</p><p>Tonsillectomy leads to complete episode resolution in many patients with PFAPA (see <a class="local">'Tonsillectomy'</a> below). Thus, it is hypothesized that local aberrant immune responses in the palatine tonsils, which are secondary lymphoid structure in the oropharynx, trigger systemic flares. The immunologic profile of the tonsils from patients with PFAPA was noted to have a lower percentage of B cells, higher percentage of CD8+ cytotoxic T cells, a higher percentage of naïve T cells, and a lower percentage of CD4+ T cells with high expression of the inhibitory molecule PD-1 in comparison with tonsils from children with sleep apnea [<a href="#rid36">36</a>]. In addition, tonsils from patients with PFAPA have high expression of T cell chemokines and proinflammatory cytokines [<a href="#rid36">36-38</a>]. In addition, tonsils from patients who do not fully meet the diagnostic criteria for PFAPA or other known periodic fever syndromes (referred to as having syndromes of undifferentiated recurrent fever [SURF]) were found to have a heightened IL-1-beta gene signature and distinct cellular composition to tonsils from patients with PFAPA. Nevertheless, most of these patients with SURF also had episode resolution with tonsillectomy [<a href="#rid39">39</a>].</p><p>The regularity in timing of fever flares is a cardinal feature of PFAPA. Possible explanations include intermittent expression or suppression of antigens or epitopes of infectious agents or an alteration in the nature or kinetics of the immunologic response [<a href="#rid40">40</a>]. However, lack of consistent seasonal or geographic clustering and the progression-free duration of PFAPA for years weigh against an infectious etiology [<a href="#rid17">17,41</a>]. In addition, no consistent differences in the presence of herpes viruses, adenovirus, and particular bacterial phyla, genera, or species on tonsils of patients with PFAPA and controls have been found [<a href="#rid36">36,42,43</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Periodic fever is the hallmark of PFAPA syndrome. Other cardinal associated features during flares include aphthous ulcers, pharyngitis (sometimes with tonsillar exudates), and cervical adenopathy.</p><p class="headingAnchor" id="H6"><span class="h2">Fever</span><span class="headingEndMark"> — </span>Fever begins abruptly, often accompanied by chills. Prodromal symptoms of malaise, irritability or mood change, sore throat, or aphthous ulcers may occur during the preceding day. Temperatures range from 38.5 to 41ºC for two to seven days and then abruptly fall to normal. Episodes rarely last for more than seven days. Thus, prolonged fever episodes should prompt consideration of other diagnoses. In most cohorts, episodes last an average of 4 to 4.5 days [<a href="#rid2">2,3,11,12,14,23,32,44</a>].</p><p>Fever episodes typically occur every two to eight weeks; the average reported in most cohorts is approximately four weeks [<a href="#rid2">2,3,11,12,14,23,32,44</a>]. Often, the start of the next episode can be predicted because of the regularity of episode timing. In other patients, the interval between episodes is approximately the same, but episodes do not occur with such perfect regularity as to allow for precise prediction of the next start date. Highly irregular episode timing should prompt evaluation for alternate diagnoses. Between febrile episodes, children with PFAPA are healthy and have normal growth and development.</p><p class="headingAnchor" id="H7"><span class="h2">Aphthous ulcers</span><span class="headingEndMark"> — </span>Aphthous ulcers (<a class="graphic graphic_picture graphicRef63475" href="/z/d/graphic/63475.html" rel="external">picture 1</a>), usually on the inner lips or buccal mucosa, occur during episodes in approximately 40 to 80 percent of patients. Occasionally, ulcerations are seen in the posterior pharynx. These ulcers may be missed on physical exam, unless the child is older and can point them out because of pain. Thus, careful physical exam during flares is required to identify ulcers. Aphthous ulcers in PFAPA are not as large or painful as the ulcers of Behçet syndrome, nor do they scar.</p><p class="headingAnchor" id="H8"><span class="h2">Pharyngitis</span><span class="headingEndMark"> — </span>Pharyngitis (<a class="graphic graphic_picture graphicRef68744" href="/z/d/graphic/68744.html" rel="external">picture 2</a>) is seen in 65 to 100 percent of patients. Exudates are often seen, may be unilateral, and may be associated with ulcerations on the palatine tonsils.</p><p class="headingAnchor" id="H2590264859"><span class="h2">Adenitis</span><span class="headingEndMark"> — </span>Cervical adenopathy accompanies the fever in 60 to 100 percent of patients. The adenopathy may be tender.</p><p class="headingAnchor" id="H9"><span class="h2">Other symptoms</span><span class="headingEndMark"> — </span>Additional symptoms outside of the oropharynx are frequently noted during flares and include abdominal pain (40 to 65 percent), joint pain (11 to 42 percent), vomiting (18 to 41 percent), and headache (18 to 65 percent) [<a href="#rid2">2,3,11,12,14,23,32,44</a>]. Abdominal pain is never sufficiently severe to warrant surgical consultation. Diarrhea, cough, coryza, and rash are reported less commonly [<a href="#rid2">2</a>]. Prominence of symptoms outside the oropharynx and atypical symptoms including arthritis and prominent rash should prompt consideration of other monogenic periodic fever syndromes. (See <a class="local">'Monogenic periodic fever syndromes'</a> below.)</p><p class="headingAnchor" id="H2362767473"><span class="h2">Fever without associated features</span><span class="headingEndMark"> — </span>Patients with stereotypical fever episodes that occur with regularity and respond to systemic glucocorticoids but lack the cardinal associated features (pharyngitis, adenitis, aphthous stomatitis) during flares have been reported to respond to tonsillectomy [<a href="#rid45">45</a>]. This suggests that the phenotypic spectrum of PFAPA is broader than initially thought.</p><p class="headingAnchor" id="H4079620330"><span class="h2">Adults versus children</span><span class="headingEndMark"> — </span>Adult patients with PFAPA have been reported [<a href="#rid4">4,46</a>]. In a report comparing 30 adults with PFAPA syndrome with 85 children with PFAPA, adults were less likely to have clockwork periodicity of episodes and pharyngitis but were more likely to have chest pain, headache, arthralgias, myalgias, ocular signs, and rashes [<a href="#rid46">46</a>]. In another comparison of 63 adults and 120 children with PFAPA, fewer adults were found to have clockwork periodicity or exudative pharyngitis and more adults were found to have arthralgia and myalgia compared with children [<a href="#rid47">47</a>].</p><p>In published cohorts in Italy and Israel, the age of fever onset of adult patients with PFAPA was between 20 and 33 years of age [<a href="#rid4">4,46,48</a>]. Some patients had episodes during childhood, which resumed after a period of remission; a few had episode recurrence after tonsillectomy in childhood. In another published series, PFAPA criteria were applied to 359 adults with recurrent fever, and 17 were found to fulfill the diagnostic criteria for PFAPA (aside from early age of onset) [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2083630264"><span class="h1">FAMILY HISTORY</span><span class="headingEndMark"> — </span>A careful history about family members who have not only recurrent fever but also recurrent tonsillitis, recurrent streptococcal pharyngitis, tonsillectomy, and recurrent aphthous ulcers will often reveal numerous family members with these medical problems. This may represent incorrectly diagnosed or reduced penetrance disease manifestations of PFAPA [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H10"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>There is no diagnostic laboratory test for PFAPA syndrome. The diagnosis is primarily made based upon clinical history and physical exam findings. Prior to recognition of the periodicity, episodes are usually ascribed to infectious tonsillitis or a viral syndrome.</p><p>In a United States cohort of patients with PFAPA, 29 of 284 throat cultures yielded Group A <em>Streptococcus </em>[<a href="#rid2">2</a>]. These "positive" throat cultures probably represent benign carriage since patients with PFAPA do not respond to penicillin therapy.</p><p>Moderate leukocytosis (13.6±4.5 x 10<sup>9</sup> cells/L) and elevation of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) [<a href="#rid2">2,14,33</a>] are usually present during episodes but normalize between attacks. Neutrophilia, monocytosis, and mild lymphopenia may also be seen during flares [<a href="#rid28">28</a>].</p><p>Twelve of 18 Israeli patients had significantly elevated serum concentrations of immunoglobulin D (IgD) during flares but not at the levels reported in the hyper-IgD syndrome (HIDS) [<a href="#rid3">3</a>]. The other immunoglobulin levels (immunoglobulin G [IgG], immunoglobulin M [IgM], and immunoglobulin A [IgA]) stayed within the normal range [<a href="#rid3">3</a>].</p><p>Unlike CRP, procalcitonin concentrations do not increase during flares; therefore, procalcitonin does not appear to have much utility in differentiating PFAPA flares from acute bacterial infection or infectious pharyngitis [<a href="#rid49">49,50</a>].</p><p>Antinuclear antibody (ANA) was present in 1 of 30, consistent with the known frequency of ANA in healthy children [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2976940646"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Patients suspected of having PFAPA should be referred to a pediatric rheumatologist, pediatric infectious disease specialist, clinical immunologist, or another specialist familiar with PFAPA unless the patient's primary care clinician is experienced with diagnosing and managing the syndrome. Because the diagnosis of PFAPA is made based upon clinical features, an experienced clinician will need to ensure that other periodic fever syndromes and recurrent infections are excluded (<a class="graphic graphic_algorithm graphicRef117726" href="/z/d/graphic/117726.html" rel="external">algorithm 1</a>). (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>PFAPA is a diagnosis of exclusion that is made on clinical grounds. Other causes of recurrent fever are first ruled out, including recurrent infection and, less commonly, fulminant or early-onset inflammatory bowel disease, Pel-Ebstein fever in lymphoma, and cyclic neutropenia. Other monogenic periodic fever syndromes are then excluded.</p><p>Careful analysis of the dates of fever episodes and physical exam during flares are critical for making a diagnosis of PFAPA. Asking patients and/or their caregiver(s) to maintain a fever diary documenting dates of fever, height of fever, and associated symptoms is helpful to determine the pattern of fever.</p><p>The primary reasons for making this diagnosis are to relieve parent/caregiver anxiety, avoid unnecessary and expensive laboratory evaluation, and prevent potentially harmful treatment. Adherence to the following clinical criteria will assure that more serious diseases associated with recurrent fever are excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>No universally accepted criteria for PFAPA have been developed. The original criteria for PFAPA published in 1989 included the following features [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of disease in early childhood</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regularly recurring episodes of fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of at least one of these associated features during flares: aphthous stomatitis, pharyngitis, and/or cervical adenitis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic intervals between flares with normal growth</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of signs of respiratory tract infection during flares and exclusion of cyclic neutropenia, other known periodic fever syndromes, immunodeficiency, or autoimmune diseases</p><p></p><p>Since then, exceptions to these criteria, including patients with onset of symptoms in adulthood and patients with no associated features during episodes, have been reported. A survey of pediatric rheumatologists and infectious disease clinicians who see patients with PFAPA indicated that many of these specialists do not require early age of onset or presence of aphthous stomatitis, pharyngitis, or cervical adenitis during episodes if they are regular in timing [<a href="#rid52">52</a>].</p><p>Other groups have proposed alternate diagnostic and classification criteria for PFAPA designed to better differentiate PFAPA from monogenic periodic fever syndromes and infectious pharyngitis [<a href="#rid53">53,54</a>]. A panel of clinicians used consensus conferences and evaluations of patient cases to devise PFAPA classification criteria for use in clinical and epidemiologic studies. They propose classifying persons with seven out of eight of the following criteria as having PFAPA: presence of pharyngotonsillitis, episode duration of three to six days, cervical lymphadenitis, periodicity and absence of diarrhea, chest pain, skin rash, and arthritis [<a href="#rid54">54</a>]. These proposed criteria require validation in multiple populations.</p><p>The primary features of the clinical criteria that we believe are important for diagnosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>More than four documented stereotypical episodes of fever occurring at regular intervals. For individual patients, intervals between attacks are nearly identical within a range of two to eight weeks. Each episode typically lasts two to seven days. It is important to confirm that the symptoms with each episode are nearly identical. It is not uncommon for patients to occasionally skip an episode expected at a particular time or to experience a change in the periodicity of their flares over time. However, considerable irregularity in episode timing should prompt consideration of other diagnoses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During flares, patients have pharyngitis, cervical lymphadenopathy, or aphthous ulcers. Thus, it is helpful to carefully examine patients during flares for the presence of these findings. However, in one study, even patients who did not have these associated symptoms but met all of the other diagnostic criteria for PFAPA had complete symptom resolution following tonsillectomy, strongly suggesting that they also have PFAPA [<a href="#rid45">45</a>]. Atypical symptoms during flares such as severe abdominal pain, chest pain, arthritis, rash, or significant vomiting or diarrhea should prompt evaluation for other conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal growth parameters and development with no symptoms or abnormal laboratory studies between episodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of symptoms (fever and pharyngitis) within a matter of hours after treatment with a 1 to 2 mg/kg oral dose of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> given as a single dose or two doses 12 to 48 hours apart [<a href="#rid2">2-5,11</a>]. (See <a class="local">'Episodic treatment'</a> below.)</p><p></p><p class="bulletIndent1">This response may be useful in distinguishing attacks of PFAPA from familial Mediterranean fever (FMF) or other hereditary autoinflammatory periodic fever syndromes [<a href="#rid3">3-5</a>] and can be used as a diagnostic criterion for PFAPA [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">We suggest giving a single oral dose of 1 to 2 mg/kg (maximum dose 60 mg) of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> at the onset of fever as part of the diagnostic evaluation. Patients may have a recrudescence of symptoms 12 to 48 hours after this first dose of prednisone/prednisolone and may require a second dose at that time. If a 1 mg/kg dose of prednisone/prednisolone was given initially, a second 1 mg/kg dose can be given if the fever returns 12 to 48 hours later. The diagnosis should be reconsidered if fever recurs after the patient receives a total of 2 mg/kg prednisone/prednisolone per episode.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Exclusion criteria</span><span class="headingEndMark"> — </span>Exclusion of other periodic fever syndromes, recurrent infectious illnesses, cyclic neutropenia, and autoimmune diseases is essential. Patients should be evaluated for the following features since the presence of any of them precludes the diagnosis of PFAPA syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – Neutropenia immediately preceding or during an attack suggests cyclic neutropenia (also called cyclic hematopoiesis), which closely resembles PFAPA. (See  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical symptoms</strong> – PFAPA attacks have stereotypical symptoms that are easily recognizable by caregivers. The following symptoms as a part of most attacks should trigger evaluation for other diagnoses: cough, coryza, severe abdominal pain, significant vomiting or diarrhea, chest pain, rash, arthritis, or significant neuromuscular symptoms.</p><p></p><p class="bulletIndent1">Genetic testing for monogenic autoinflammatory diseases is suggested for patients with the above symptoms, except cough and coryza, which are more suggestive of recurrent infectious illnesses [<a href="#rid55">55,56</a>]. Alternate diagnoses should also be considered in patients with extreme irregularity in episode duration and timing, very early or very late age of onset, and episodes lasting longer than one week. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated acute-phase reactants between attacks</strong> – Laboratory evidence of a persistently elevated acute-phase protein response (eg, C-reactive protein [CRP]) during asymptomatic periods suggests a chronic illness with intermittent flares rather than a true periodic disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of episode resolution after one or two doses of a glucocorticoid </strong>– Lack of a response should prompt evaluation for hereditary autoinflammatory periodic fever syndromes. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The approach to evaluating a child with recurrent fever is presented in the algorithm (<a class="graphic graphic_algorithm graphicRef117726" href="/z/d/graphic/117726.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2741887435"><span class="h2">Cyclic neutropenia</span><span class="headingEndMark"> — </span>The only other childhood disorder with truly periodic fever is cyclic neutropenia (also called cyclic hematopoiesis). Most patients with cyclic neutropenia exhibit a 21-day cycle (range 14 to 35 days) compared with the typical 28-day (range 26 to 30) cycle for PFAPA, and the period is consistent within each patient. Neutropenia during episodes is seen with cyclic neutropenia but not PFAPA. In addition, patients with cyclic neutropenia may develop extensive gingival disease compared with the more limited and intermittent aphthous ulcers seen in PFAPA. An infectious disease or malignancy is rarely diagnosed in an individual who has predictably periodic fever over months to years [<a href="#rid57">57,58</a>]. If cyclic neutropenia is suspected, genetic testing and serial complete blood counts (CBCs) should be performed. (See  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.)</p><p class="headingAnchor" id="H2411570709"><span class="h2">Monogenic periodic fever syndromes</span><span class="headingEndMark"> — </span>Recurrent fevers that are not truly periodic (ie, do not have a consistent interval between episodes) suggest one of the monogenic periodic fever syndromes, including hyperimmunoglobulin D (hyper-IgD) syndrome (HIDS), familial Mediterranean fever (FMF), tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS), or the cryopyrin-associated periodic fevers (CAPS). Screening panels for mutations in genes associated with the known monogenic periodic fever syndromes or autoinflammatory diseases are available through several reference laboratories and should be sent in patients with symptoms atypical for PFAPA. (See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a> and <a class="local">'Exclusion criteria'</a> above.)</p><p>FMF is often suspected in patients with PFAPA. Unlike FMF, PFAPA is a periodic disease, while attacks of FMF occur at random. In addition, tonsillitis is not seen during FMF flares. Although PFAPA patients may present with mild-to-moderate abdominal and/or joint pain, FMF presents with acute abdomen and/or arthritis. FMF attacks are typically shorter than PFAPA attacks and cannot be fully aborted by glucocorticoids. HIDS flares can also closely resemble PFAPA. The presence of significant diarrhea or vomiting, lymphadenopathy outside of the cervical area, and episodes triggered by immunization or stress are suggestive of HIDS [<a href="#rid59">59</a>]. Patients with TRAPS typically have flares that last longer than one week and have periorbital symptoms and migratory rashes and myalgias. Patients with CAPS have a range of disease manifestations ranging from mild disease with fever, arthralgia, and urticarial rash during flares to severe disease with hearing loss, meningitis, and bony abnormalities.</p><p class="headingAnchor" id="H15"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>PFAPA is a relatively benign and self-limited disease with episode resolution in most patients by age 10 years [<a href="#rid2">2,3,5,11,12,17</a>]. With time, the episodes become less severe, less frequent, and shorter in duration [<a href="#rid17">17</a>]. The mean duration of attacks ranges from 4.5 to 8 years. Those with symptoms that persist into adolescence tend to have episodes that are shorter in duration and that occur less frequently [<a href="#rid17">17</a>]. Affected children grow and develop normally and experience no long-term sequelae [<a href="#rid17">17</a>]. Children with later age of episode onset, family history of PFAPA, and without headache during flares had earlier episode resolution in an analysis of 466 patients in Turkey [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The optimal management strategy for patients with PFAPA is dependent upon response to treatments and how disruptive the attacks are to the child and their caregivers and household members. Given the favorable natural history, treatment of any kind is optional. The risks of each treatment strategy must be weighed against adverse effects of allowing the child to continue to have regular febrile episodes. A group of expert clinicians developed four treatment arms as part of consensus treatment plans (CTPs) to be tested in future treatment trials [<a href="#rid61">61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic management with antipyretics, such as <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs)</p><p class="bulletIndent1"><span class="glyph">●</span>Abortive therapy during episodes with glucocorticoids</p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic therapy with <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> or <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical therapy with tonsillectomy</p><p></p><p>The decision to treat or not and which strategy to use should be made by the patient and parent(s)/caregiver(s) in conjunction with their clinician. Questions to be considered in this decision include:</p><p class="bulletIndent1"><span class="glyph">●</span>Can the child afford to miss several days a month of school?</p><p class="bulletIndent1"><span class="glyph">●</span>Can a parent or caregiver miss work to care for a febrile child?</p><p class="bulletIndent1"><span class="glyph">●</span>Does familial stress related to the illness justify the potential risk of treatment?</p><p></p><p class="headingAnchor" id="H417372785"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>If the patient and parent(s)/caregiver(s) wish <strong>not</strong> to treat, given that PFAPA is a self-limited disease with no known long-term sequelae, observation or treatment with antipyretics alone is acceptable (<a class="graphic graphic_algorithm graphicRef112469" href="/z/d/graphic/112469.html" rel="external">algorithm 2</a>). We typically find that antipyretics are ineffective in controlling the symptoms of PFAPA aside from fever.</p><p>If the patient and parent(s)/caregiver(s) wish to treat episodes, we initially use oral glucocorticoids since response to glucocorticoids may have some diagnostic value as well. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p>Glucocorticoid treatment may increase the frequency of episodes. In these patients, a trial of prophylaxis with <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> or <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> is an option (with episodic glucocorticoids for breakthrough episodes). Tonsillectomy is also an option at this point, particularly for those patients who do not respond to or tolerate medical management or whose episodes are highly disruptive and affect quality of life. The third alternative is to treat episodes with antipyretics only. Patient and parent(s)/caregiver(s) preferences, the impact of fever episodes on their quality of life , and potential adverse effects of therapy should be considered in selecting the management plan.</p><p class="headingAnchor" id="H17"><span class="h2">Episodic treatment</span><span class="headingEndMark"> — </span>Glucocorticoids, such as <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> 1 to 2 mg/kg orally, rapidly relieve the fever that occur in PFAPA episodes, usually within a few hours [<a href="#rid3">3-5,11</a>]. Other symptoms, such as aphthous stomatitis and cervical adenopathy, may take longer to resolve. The glucocorticoid dose should be administered as soon as possible after the episode begins since delayed administration may reduce efficacy. Most patients have episode resolution with one dose of glucocorticoid, but approximately 20 to 25 percent require a second dose 12 to 24 hours later due to recrudescence of the fever [<a href="#rid11">11,62</a>].</p><p>Many parents/caregivers worry about the potential side effects of glucocorticoid therapy. Toxicity related to the low doses of glucocorticoids used in PFAPA (generally ≤2 mg/kg per month and given approximately once a month), aside from possible restlessness and changes in mood on the days of administration of the drug, have not been reported in published studies, although no studies have specifically examined what dose of glucocorticoid can safely be used long term in patients with PFAPA.</p><p>The major drawback to glucocorticoid treatment in PFAPA is that it may result in shortening of the interval between attacks. This occurs in 19 to 50 percent of patients [<a href="#rid3">3,11,23,41</a>]. Episodes may occur as frequently as one week apart. It is unknown whether higher doses of glucocorticoid are less likely to cause an increase in episode frequency. With discontinuation of glucocorticoid therapy, episode frequency typically returns to the baseline rate.</p><p>For patients with an increase in episode frequency requiring more than 2 mg/kg of glucocorticoid per month, alternate therapies include <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> or <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> prophylaxis or tonsillectomy, although the maximum dose of glucocorticoid per month that can be used without fear of adverse effects in children is unknown. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) PFAPA work group consensus treatment plan advises use of alternate treatment options if the fever interval shortens to less than 21 days with 2 mg/kg of glucocorticoid per flare [<a href="#rid61">61</a>]. (See <a class="local">'Preventive or prophylactic treatment'</a> below and <a class="local">'Tonsillectomy'</a> below.)</p><p>In patients who have responded to a test dose of glucocorticoid, subsequent episodes may be treated with a single dose of 1 to 2 mg/kg <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (maximum 60 mg) at fever onset. With an ineffective dose, the fever will recur 12 to 48 hours after administration of the glucocorticoid. If 1 mg/kg of prednisone/prednisolone is initially given and fever returns 12 to 48 hours after the dose, a second 1 mg/kg dose can be given during the episode. In these patients, a single 2 mg/kg dose should be trialed for subsequent episodes. Patients requiring more than 2 mg/kg of glucocorticoid per episode should be evaluated for other periodic fever syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>Treatment of episodes is continued until the patient stops having episodes or the patient and parent(s)/caregiver(s) wishes to do a trial off of therapy because episodes have become less severe.</p><p>The most commonly reported side effects of glucocorticoid treatment are restlessness and sleep disruption.</p><p class="headingAnchor" id="H1989978241"><span class="h2">Preventive or prophylactic treatment</span><span class="headingEndMark"> — </span>Prophylactic therapy (<a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> or <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a>) is an option in patients who have an increase in frequency of episodes on glucocorticoids.</p><p class="headingAnchor" id="H1434859948"><span class="h3">Cimetidine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">Cimetidine</a> may increase the episode interval, decrease episode severity, or lead to resolution of PFAPA episodes. No randomized, controlled trials of cimetidine prophylaxis have been performed for PFAPA, but beneficial effects of prophylactic therapy with cimetidine have been noted in some small case series and in case reports. Cimetidine is usually given 20 to 40 mg/kg/day in divided doses every 12 hours (maximum dose 1200 mg/day). If cimetidine reduces the frequency of recurrent fevers or eliminates them altogether, an attempt to discontinue the drug is appropriate after 6 to 12 months of continuous use. Episodic glucocorticoids are typically still given for breakthrough episodes.</p><p>In cohort studies, approximately a quarter of patients (24 to 27 percent) had complete resolution of fever episodes while taking <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a>, and another 24 to 32 percent report partial efficacy with improvement in symptom frequency or severity [<a href="#rid2">2,11,23</a>]. The remainder reported no effect. Cimetidine was typically well tolerated.</p><p class="headingAnchor" id="H2235274487"><span class="h3">Colchicine</span><span class="headingEndMark"> — </span>Another option for prophylaxis in patients is <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> (target dose 0.5 to 1.2 mg/day in children four to six years old and 1 to 1.8 mg/day in children over six years of age). Few trials of colchicine have been conducted, with most performed in Israel, where a large proportion of patients carry pathogenic <em>MEFV</em> variants.</p><p>One open-label, randomized study of 18 patients with PFAPA in Israel showed that patients on <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> prophylaxis had a reduced number of PFAPA episodes compared with controls [<a href="#rid63">63</a>]. Patients were randomly assigned to no treatment for six months or observation for three months followed by colchicine treatment for three months. Patients in the treatment group had fewer PFAPA episodes while on colchicine therapy (4.9±2.3 versus 1.6±1.2 episodes per three-month period), while no change in the rate of episodes was noted in the control group.</p><p>In a case series from Israel, prophylaxis with <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> (0.5 to 1 mg/day) was offered to nine patients with PFAPA episodes occurring at intervals of ≤14 days [<a href="#rid64">64</a>]. All of these patients also received glucocorticoids for episodes. The patients were followed for an average of two years (range 6 to 48 months) on colchicine. In eight of nine patients, treatment with colchicine was associated with an increased interval between episodes (the average interval increased from 1.7 to 8.4 weeks). In two patients, discontinuation of colchicine was associated with an increased frequency of episodes. Two patients were compound heterozygotes for <em>MEFV</em> mutations, whereas the others did not have pathogenic <em>MEFV</em> variants.</p><p>In a retrospective study of 20 patients with PFAPA in France who received <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a>, nine patients had a 50 percent decrease in episode frequency [<a href="#rid65">65</a>]. Another study of 13 patients in Spain with PFAPA episodes that did not fully respond to a glucocorticoid or occurred more frequently than every 14 days found that patients on daily colchicine had less severe and less frequent flares [<a href="#rid66">66</a>].</p><p>The main side effects of <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a> are abdominal pain, diarrhea, and lactose intolerance. The dose should be slowly increased over several weeks starting from 0.3 or 0.5 mg/day to the desired dose to mitigate these side effects.</p><p class="headingAnchor" id="H20"><span class="h2">Tonsillectomy</span><span class="headingEndMark"> — </span>Tonsillectomy is an effective surgical treatment for many patients with PFAPA, particularly in patients who fail to respond to medical management (glucocorticoids with or without preventive or prophylactic therapy) or have considerable disruption in their lives due to episode frequency. Patients who do not strictly meet the diagnostic criteria for PFAPA should be evaluated by a specialist with experience with PFAPA prior to undergoing tonsillectomy. The risks of surgery and benign long-term nature of PFAPA should also be taken into account when deciding the management strategy. Most patients with PFAPA continue to have aphthous stomatitis after tonsillectomy [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/88054.html" rel="external">"Tonsillectomy (with or without adenoidectomy) in children: Postoperative care and complications"</a>.)</p><p>Most case reports and case series support the effectiveness of tonsillectomy with or without adenoidectomy in inducing remission or decreasing symptom frequency and severity in the majority of patients with PFAPA [<a href="#rid2">2-4,11,12,39,41,45,68-77</a>]. The largest observational study followed 102 patients for an average of 43 months following tonsillectomy; 99 (97 percent) had complete resolution of PFAPA episodes [<a href="#rid76">76</a>]. Two randomized trials have confirmed these observational findings [<a href="#rid78">78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first trial, 26 children with five or more fever episodes diagnosed as PFAPA were assigned to treatment with tonsillectomy or follow-up alone [<a href="#rid79">79</a>]. Six months after randomization, all of the 14 children in the tonsillectomy group, but only 6 of 12 of the children in the follow-up group, were symptom free. However, this study had several limitations. Eleven of these patients had no symptoms other than fever during a flare; seven of these were in the tonsillectomy group [<a href="#rid5">5</a>]. One-half of the patients not subjected to tonsillectomy had remission within six months. This rapid rate of remission is very atypical.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second randomized trial used standard diagnostic criteria for PFAPA [<a href="#rid80">80</a>]. In this trial, 39 patients were assigned to treatment with either adenotonsillectomy or expectant management. Sixty-three percent in the surgery group had immediate and complete resolution of symptoms, and the remainder had a decrease in the frequency and severity of episodes. Only 1 of 20 children in the control group went into remission during the 18-month follow-up period.</p><p></p><p>A retrospective study of 108 patients who had undergone tonsillectomy for complete or incomplete PFAPA revealed that all of the 50 patients who did not have any of the associated oropharyngeal features (pharyngitis, adenitis, or aphthous stomatitis) during flares, which the authors define as incomplete PFAPA, had an excellent response to tonsillectomy [<a href="#rid45">45</a>]. Among five persons with recurrence of febrile episodes following tonsillectomy, regrowth of palatine tonsil tissue was documented in four patients, suggesting that tonsillar regrowth may lead to relapse [<a href="#rid77">77</a>].</p><p>Among adults with PFAPA, small case series suggest that tonsillectomy in adulthood may be less effective than in children [<a href="#rid47">47,48,81</a>].</p><p class="headingAnchor" id="H7323284"><span class="h2">Experimental therapy</span><span class="headingEndMark"> — </span>Interleukin (IL) 1 antagonists have been trialed because elevated IL-1 beta-related transcripts are associated with PFAPA flares. In a pilot study, five patients were treated with <a class="drug drug_pediatric" data-topicid="13251" href="/z/d/drug information/13251.html" rel="external">anakinra</a>, a recombinant IL-1 receptor antagonist, during flares [<a href="#rid28">28</a>]. All patients demonstrated clinical improvement and decreased inflammatory markers. In another study, anakinra (100 mg/day) was given for five to seven days during fever episodes to four adult patients with PFAPA, and one responded well [<a href="#rid47">47</a>]. <a class="drug drug_pediatric" data-topicid="17066" href="/z/d/drug information/17066.html" rel="external">Canakinumab</a> was effective in two adults. Doses of anakinra as low as 0.5 mg/kg per day have been used successfully; therefore, gradually lower doses can be trialed in patients who respond [<a href="#rid82">82</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Vitamin D can act as an immunoregulatory factor, in addition to its role in calcium homeostasis and bone metabolism. In two studies, patients with PFAPA had significantly lower levels of 25 (OH) vitamin D compared with healthy controls [<a href="#rid83">83,84</a>]. Vitamin D levels were at their lowest during the winter (as is true in most people in colder northern climates), and, in this cohort, they correlated with number of fever episodes and C-reactive protein (CRP) levels. Supplementation with vitamin D during the winter months led to a decrease in the number and duration of febrile episodes, but vitamin D has not been evaluated in a controlled trial for PFAPA. Since the natural history of PFAPA is for episodes to become less frequent and severe over time, controlled trials of treatments are essential to prove their efficacy.</p><p>A randomized crossover trial in Italy of 22 children with PFAPA suggested that pidotimod, an immunostimulant, was safe and effective in reducing the frequency and severity of febrile flares [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – PFAPA syndrome is a complex genetic disease and one of the most common periodic fever syndromes. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – It usually presents in childhood and is characterized by periodic fevers at regular intervals of two to eight weeks and by stereotypical clinical features of pharyngitis, aphthous ulcers, and cervical adenitis. Children are asymptomatic between episodes. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PFAPA is based upon clinical criteria and the exclusion of other causes of recurrent fevers (<a class="graphic graphic_algorithm graphicRef117726" href="/z/d/graphic/117726.html" rel="external">algorithm 1</a>). In addition, a single dose of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> or <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (1 to 2 mg/kg) given at the onset of fever can be used as a diagnostic tool. Fever usually resolves within a matter of hours after receiving a glucocorticoid, but some patients may require a second 1 mg/kg dose 12 to 48 hours later if fever returns and only 1 mg/kg was given for the first dose. Clinical features that <strong>exclude</strong> PFAPA include the presence of neutropenia before or during an episode, the presence of atypical symptoms (ie, cough, coryza, severe abdominal pain, diarrhea, severe vomiting, rash, arthritis, or neurologic deficits) during febrile episodes, an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) between attacks, or impaired growth. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – PFAPA is a self-limited disease with no long-term sequelae. Consensus treatment plans from a panel of expert clinicians outlines four treatment strategies including symptomatic treatment with antipyretics, abortive treatment with glucocorticoids, prophylaxis with <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> or <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">colchicine</a>, and surgical treatment with tonsillectomy. A decision of whether and how to treat PFAPA is based upon severity and duration of episodes, impact on quality of life, and preference of the patient/parent(s)/caregiver(s) (<a class="graphic graphic_algorithm graphicRef112469" href="/z/d/graphic/112469.html" rel="external">algorithm 2</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Episodic treatment</strong> – In patients or their parent(s)/caregiver(s) who opt for episodic treatment with a glucocorticoid, episodes may be treated with a single dose of 1 to 2 mg/kg of oral <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>/<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (maximum dose 60 mg) at the onset of fever. If 1 mg/kg of prednisone/prednisolone does not abort the episode and fever returns 12 to 48 hours after the dose, a second 1 mg/kg dose can be given during the episode. For subsequent episodes, a single 2 mg/kg dose should be trialed. Treatment of episodes is continued until the patient stops having episodes or wishes to do a trial off of therapy. (See <a class="local">'Episodic treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Daily therapy</strong> – <a class="drug drug_pediatric" data-topicid="13179" href="/z/d/drug information/13179.html" rel="external">Colchicine</a> and <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">cimetidine</a> as daily therapies may decrease episode frequency, and cimetidine may also lead to remission in some patients. (See <a class="local">'Preventive or prophylactic treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tonsillectomy</strong> – Tonsillectomy leads to complete episode resolution in the majority of patients with PFAPA, including those with no associated features aside from fever during flares. We typically use tonsillectomy in patients with PFAPA who fail medical management (glucocorticoids with or without preventive or prophylactic therapy) or have considerable disruption in their life due to fever episodes. There are rare reports of patients with recurrence of flares after tonsillectomy, which may be due to tonsillar regrowth. (See <a class="local">'Tonsillectomy'</a> above.)</p><p></p><p class="headingAnchor" id="H1976719911"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Shai Padeh, MD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987; 110:43.</a></li><li><a class="nounderline abstract_t">Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 1999; 135:15.</a></li><li><a class="nounderline abstract_t">Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999; 135:98.</a></li><li><a class="nounderline abstract_t">Padeh S, Stoffman N, Berkun Y. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J 2008; 10:358.</a></li><li><a class="nounderline abstract_t">Manthiram K, Lapidus S, Edwards K. Unraveling the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis through genetic, immunologic, and microbiologic discoveries: an update. Curr Opin Rheumatol 2017; 29:493.</a></li><li><a class="nounderline abstract_t">McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133.</a></li><li><a class="nounderline abstract_t">Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 2017; 18:832.</a></li><li><a class="nounderline abstract_t">Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140:784.</a></li><li><a class="nounderline abstract_t">Manthiram K, Preite S, Dedeoglu F, et al. Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis. Proc Natl Acad Sci U S A 2020; 117:14405.</a></li><li><a class="nounderline abstract_t">Sampaio IC, Rodrigo MJ, Monteiro Marques JG. Two siblings with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome. Pediatr Infect Dis J 2009; 28:254.</a></li><li><a class="nounderline abstract_t">Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010; 99:178.</a></li><li><a class="nounderline abstract_t">Førsvoll J, Kristoffersen EK, Øymar K. Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome; a population-based study. Acta Paediatr 2013; 102:187.</a></li><li><a class="nounderline abstract_t">Valenzuela PM, Majerson D, Tapia JL, Talesnik E. Syndrome of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) in siblings. Clin Rheumatol 2009; 28:1235.</a></li><li><a class="nounderline abstract_t">Hofer M, Pillet P, Cochard MM, et al. International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford) 2014; 53:1125.</a></li><li><a class="nounderline abstract_t">Taniuchi S, Nishikomori R, Iharada A, et al. MEFV Variants in Patients with PFAPA Syndrome in Japan. Open Rheumatol J 2013; 7:22.</a></li><li><a class="nounderline abstract_t">Amarilyo G, Harel L, Abu Ahmad S, et al. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome - Is It Related to Ethnicity? An Israeli Multicenter Cohort Study. J Pediatr 2020; 227:268.</a></li><li><a class="nounderline abstract_t">Wurster VM, Carlucci JG, Feder HM Jr, Edwards KM. Long-term follow-up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. J Pediatr 2011; 159:958.</a></li><li><a class="nounderline abstract_t">Adachi M, Watanabe A, Nishiyama A, et al. Familial cases of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. J Pediatr 2011; 158:155.</a></li><li><a class="nounderline abstract_t">Sampaio IC, Rodrigo MJ, Monteiro Marques JG. Two siblings with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome. Pediatr Infect Dis J 2009; 28:254.</a></li><li><a class="nounderline abstract_t">Antón-Martín P, Ortiz Movilla R, Guillén Martín S, et al. PFAPA syndrome in siblings. Is there a genetic background? Eur J Pediatr 2011; 170:1563.</a></li><li><a class="nounderline abstract_t">Cochard M, Clet J, Le L, et al. PFAPA syndrome is not a sporadic disease. Rheumatology (Oxford) 2010; 49:1984.</a></li><li><a class="nounderline abstract_t">Di Gioia SA, Bedoni N, von Scheven-Gête A, et al. Analysis of the genetic basis of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Sci Rep 2015; 5:10200.</a></li><li><a class="nounderline abstract_t">Manthiram K, Nesbitt E, Morgan T, Edwards KM. Family History in Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42:698.</a></li><li><a class="nounderline abstract_t">Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45:202.</a></li><li><a class="nounderline abstract_t">Kolly L, Busso N, von Scheven-Gete A, et al. Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1β production. J Allergy Clin Immunol 2013; 131:1635.</a></li><li><a class="nounderline abstract_t">Stojanov S, Hoffmann F, Kéry A, et al. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 2006; 17:90.</a></li><li><a class="nounderline abstract_t">Stojanov S, Lapidus S, Chitkara P, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 2011; 108:7148.</a></li><li><a class="nounderline abstract_t">Brown KL, Wekell P, Osla V, et al. Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. BMC Pediatr 2010; 10:65.</a></li><li><a class="nounderline abstract_t">Scattoni R, Verrotti A, Rinaldi VE, et al. Genital ulcer as a new clinical clue to PFAPA syndrome. Clin Exp Dermatol 2015; 40:286.</a></li><li><a class="nounderline abstract_t">Cantarini L, Vitale A, Bersani G, et al. PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol 2016; 35:501.</a></li><li><a class="nounderline abstract_t">Celiksoy MH, Ogur G, Yaman E, et al. Could familial Mediterranean fever gene mutations be related to PFAPA syndrome? Pediatr Allergy Immunol 2016; 27:78.</a></li><li><a class="nounderline abstract_t">Berkun Y, Levy R, Hurwitz A, et al. The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011; 40:467.</a></li><li><a class="nounderline abstract_t">Pehlivan E, Adrovic A, Sahin S, et al. PFAPA Syndrome in a Population with Endemic Familial Mediterranean Fever. J Pediatr 2018; 192:253.</a></li><li><a class="nounderline abstract_t">Yildiz M, Adrovic A, Ulkersoy I, et al. The role of Mediterranean fever gene variants in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome. Eur J Pediatr 2021; 180:1051.</a></li><li><a class="nounderline abstract_t">Dytrych P, Krol P, Kotrova M, et al. Polyclonal, newly derived T cells with low expression of inhibitory molecule PD-1 in tonsils define the phenotype of lymphocytes in children with Periodic Fever, Aphtous Stomatitis, Pharyngitis and Adenitis (PFAPA) syndrome. Mol Immunol 2015; 65:139.</a></li><li><a class="nounderline abstract_t">Luu I, Sharma A, Guaderrama M, et al. Immune Dysregulation in the Tonsillar Microenvironment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome. J Clin Immunol 2020; 40:179.</a></li><li><a class="nounderline abstract_t">Hara M, Morimoto N, Suzuki N, et al. Transcriptome analysis reveals two distinct endotypes and putative immune pathways in tonsils from children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Allergy 2021; 76:359.</a></li><li><a class="nounderline abstract_t">Luu I, Nation J, Page N, et al. Undifferentiated recurrent fevers in pediatrics are clinically distinct from PFAPA syndrome but retain an IL-1 signature. Clin Immunol 2021; 226:108697.</a></li><li><a class="nounderline abstract_t">Long SS. Syndrome of Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA)--what it isn't. What is it? J Pediatr 1999; 135:1.</a></li><li><a class="nounderline abstract_t">Tasher D, Somekh E, Dalal I. PFAPA syndrome: new clinical aspects disclosed. Arch Dis Child 2006; 91:981.</a></li><li><a class="nounderline abstract_t">Lantto U, Koivunen P, Tapiainen T, et al. Microbes of the tonsils in PFAPA (Periodic Fever, Aphtous stomatitis, Pharyngitis and Adenitis) syndrome - a possible trigger of febrile episodes. APMIS 2015; 123:523.</a></li><li><a class="nounderline abstract_t">Tejesvi MV, Uhari M, Tapiainen T, et al. Tonsillar microbiota in children with PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and adenitis) syndrome. Eur J Clin Microbiol Infect Dis 2016; 35:963.</a></li><li><a class="nounderline abstract_t">Perko D, Debeljak M, Toplak N, Avčin T. Clinical features and genetic background of the periodic Fever syndrome with aphthous stomatitis, pharyngitis, and adenitis: a single center longitudinal study of 81 patients. Mediators Inflamm 2015; 2015:293417.</a></li><li><a class="nounderline abstract_t">Lantto U, Koivunen P, Tapiainen T, Renko M. Long-Term Outcome of Classic and Incomplete PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis) Syndrome after Tonsillectomy. J Pediatr 2016; 179:172.</a></li><li><a class="nounderline abstract_t">Rigante D, Vitale A, Natale MF, et al. A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clin Rheumatol 2017; 36:463.</a></li><li><a class="nounderline abstract_t">Sicignano LL, Rigante D, Moccaldi B, et al. Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting. Adv Ther 2021; 38:1078.</a></li><li><a class="nounderline abstract_t">Cantarini L, Vitale A, Bartolomei B, et al. Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clin Exp Rheumatol 2012; 30:269.</a></li><li><a class="nounderline abstract_t">Yoshihara T, Imamura T, Yokoi K, et al. Potential use of procalcitonin concentrations as a diagnostic marker of the PFAPA syndrome. Eur J Pediatr 2007; 166:621.</a></li><li><a class="nounderline abstract_t">Kanik A, Eliacik K, Kanik ET, Tekindal MA. Clinical Usefulness of Acute-Phase Markers in Distinguishing between PFAPA and Other Exudative Tonsillitis Causes: A Methodological Study. J Trop Pediatr 2021; 67.</a></li><li><a class="nounderline abstract_t">Marshall GS, Edwards KM, Lawton AR. PFAPA syndrome. Pediatr Infect Dis J 1989; 8:658.</a></li><li><a class="nounderline abstract_t">Manthiram K, Li SC, Hausmann JS, et al. Physicians' perspectives on the diagnosis and management of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Rheumatol Int 2017; 37:883.</a></li><li><a class="nounderline abstract_t">Takeuchi Y, Shigemura T, Kobayashi N, et al. Clinical features and new diagnostic criteria for the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. Int J Rheum Dis 2019; 22:1489.</a></li><li><a class="nounderline abstract_t">Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019; 78:1025.</a></li><li><a class="nounderline abstract_t">Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823.</a></li><li><a class="nounderline abstract_t">Gattorno M, Caorsi R, Meini A, et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009; 124:e721.</a></li><li><a class="nounderline abstract_t">Knockaert DC, Vanneste LJ, Bobbaers HJ. Recurrent or episodic fever of unknown origin. Review of 45 cases and survey of the literature. Medicine (Baltimore) 1993; 72:184.</a></li><li><a class="nounderline abstract_t">Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999; 134:53.</a></li><li><a class="nounderline abstract_t">Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015; 74:799.</a></li><li><a class="nounderline abstract_t">Yildiz M, Haslak F, Adrovic A, et al. Independent risk factors for resolution of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome within 4 years after the disease onset. Clin Rheumatol 2021; 40:1959.</a></li><li><a class="nounderline abstract_t">Amarilyo G, Rothman D, Manthiram K, et al. Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology research alliance (CARRA) PFAPA work group. Pediatr Rheumatol Online J 2020; 18:31.</a></li><li class="breakAll">Manthiram K, National Institutes of Health, 2017, personal communication.</li><li><a class="nounderline abstract_t">Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum 2016; 45:471.</a></li><li><a class="nounderline abstract_t">Tasher D, Stein M, Dalal I, Somekh E. Colchicine prophylaxis for frequent periodic fever, aphthous stomatitis, pharyngitis and adenitis episodes. Acta Paediatr 2008; 97:1090.</a></li><li><a class="nounderline abstract_t">Dusser P, Hentgen V, Neven B, Koné-Paut I. Is colchicine an effective treatment in periodic fever, aphtous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome? Joint Bone Spine 2016; 83:406.</a></li><li><a class="nounderline abstract_t">Quintana-Ortega C, Seoane-Reula E, Fernández L, et al. Colchicine treatment in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study in Spain. Eur J Rheumatol 2021; 8:73.</a></li><li class="breakAll">Manthiram K, National Institutes of Health, 2018, personal communication.</li><li><a class="nounderline abstract_t">Galanakis E, Papadakis CE, Giannoussi E, et al. PFAPA syndrome in children evaluated for tonsillectomy. Arch Dis Child 2002; 86:434.</a></li><li><a class="nounderline abstract_t">Dahn KA, Glode MP, Chan KH. Periodic fever and pharyngitis in young children: a new disease for the otolaryngologist? Arch Otolaryngol Head Neck Surg 2000; 126:1146.</a></li><li><a class="nounderline abstract_t">Berlucchi M, Meini A, Plebani A, et al. Update on treatment of Marshall's syndrome (PFAPA syndrome): report of five cases with review of the literature. Ann Otol Rhinol Laryngol 2003; 112:365.</a></li><li><a class="nounderline abstract_t">Wong KK, Finlay JC, Moxham JP. Role of Tonsillectomy in PFAPA Syndrome. Arch Otolaryngol Head Neck Surg 2008; 134:16.</a></li><li><a class="nounderline abstract_t">Licameli G, Jeffrey J, Luz J, et al. Effect of adenotonsillectomy in PFAPA syndrome. Arch Otolaryngol Head Neck Surg 2008; 134:136.</a></li><li><a class="nounderline abstract_t">Parikh SR, Reiter ER, Kenna MA, Roberson D. Utility of tonsillectomy in 2 patients with the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. Arch Otolaryngol Head Neck Surg 2003; 129:670.</a></li><li><a class="nounderline abstract_t">Pignataro L, Torretta S, Pietrogrande MC, et al. Outcome of tonsillectomy in selected patients with PFAPA syndrome. Arch Otolaryngol Head Neck Surg 2009; 135:548.</a></li><li><a class="nounderline abstract_t">Garavello W, Pignataro L, Gaini L, et al. Tonsillectomy in children with periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr 2011; 159:138.</a></li><li><a class="nounderline abstract_t">Licameli G, Lawton M, Kenna M, Dedeoglu F. Long-term surgical outcomes of adenotonsillectomy for PFAPA syndrome. Arch Otolaryngol Head Neck Surg 2012; 138:902.</a></li><li><a class="nounderline abstract_t">Lantto U, Koivunen P, Tapiainen T, Renko M. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome: Relapse and Tonsillar Regrowth After Childhood Tonsillectomy. Laryngoscope 2021; 131:E2149.</a></li><li><a class="nounderline abstract_t">Burton MJ, Pollard AJ, Ramsden JD, et al. Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database Syst Rev 2019; 12:CD008669.</a></li><li><a class="nounderline abstract_t">Renko M, Salo E, Putto-Laurila A, et al. A randomized, controlled trial of tonsillectomy in periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr 2007; 151:289.</a></li><li><a class="nounderline abstract_t">Garavello W, Romagnoli M, Gaini RM. Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study. J Pediatr 2009; 155:250.</a></li><li><a class="nounderline abstract_t">Wu D, Shen M, Zeng X. Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis in Chinese adult patients. Clin Exp Rheumatol 2019; 37 Suppl 121:116.</a></li><li><a class="nounderline abstract_t">Yazgan H, Gültekin E, Yazıcılar O, et al. Comparison of conventional and low dose steroid in the treatment of PFAPA syndrome: preliminary study. Int J Pediatr Otorhinolaryngol 2012; 76:1588.</a></li><li><a class="nounderline abstract_t">Stagi S, Bertini F, Rigante D, Falcini F. Vitamin D levels and effects of vitamin D replacement in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Int J Pediatr Otorhinolaryngol 2014; 78:964.</a></li><li><a class="nounderline abstract_t">Nalbantoğlu A, Nalbantoğlu B. Vitamin D deficiency as a risk factor for PFAPA syndrome. Int J Pediatr Otorhinolaryngol 2019; 121:55.</a></li><li><a class="nounderline abstract_t">Manti S, Filosco F, Parisi GF, et al. Proposal for a new therapeutic high dosage of Pidotimod in children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: a randomized controlled study. Ital J Pediatr 2020; 46:106.</a></li></ol></div><div id="topicVersionRevision">Topic 5953 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3794885" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Syndrome of periodic fever, pharyngitis, and aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393598" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Periodic fever syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393612" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18605359" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28557837" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Unraveling the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis through genetic, immunologic, and microbiologic discoveries: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199409" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28722725" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20303869" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Autoinflammatory disease reloaded: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32518111" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19209090" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Two siblings with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889105" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A clinical review of 105 patients with PFAPA (a periodic fever syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23106338" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome; a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593600" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Syndrome of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) in siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24505122" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23847694" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : MEFV Variants in Patients with PFAPA Syndrome in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32805260" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome - Is It Related to Ethnicity? An Israeli Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798555" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term follow-up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074183" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial cases of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19209090" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Two siblings with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537926" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : PFAPA syndrome in siblings. Is there a genetic background?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20601652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : PFAPA syndrome is not a sporadic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988833" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Analysis of the genetic basis of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565549" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Family History in Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20622878" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23006543" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1βproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840027" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21478439" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20819226" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511245" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genital ulcer as a new clinical clue to PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25665824" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26360812" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Could familial Mediterranean fever gene mutations be related to PFAPA syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828792" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29031862" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : PFAPA Syndrome in a Population with Endemic Familial Mediterranean Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33051715" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The role of Mediterranean fever gene variants in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25656804" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Polyclonal, newly derived T cells with low expression of inhibitory molecule PD-1 in tonsils define the phenotype of lymphocytes in children with Periodic Fever, Aphtous Stomatitis, Pharyngitis and Adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31807979" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Immune Dysregulation in the Tonsillar Microenvironment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32593215" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transcriptome analysis reveals two distinct endotypes and putative immune pathways in tonsils from children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33636366" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Undifferentiated recurrent fevers in pediatrics are clinically distinct from PFAPA syndrome but retain an IL-1 signature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393593" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Syndrome of Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA)--what it isn't. What is it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595648" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : PFAPA syndrome: new clinical aspects disclosed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907769" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microbes of the tonsils in PFAPA (Periodic Fever, Aphtous stomatitis, Pharyngitis and Adenitis) syndrome - a possible trigger of febrile episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025724" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tonsillar microbiota in children with PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and adenitis) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25821352" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical features and genetic background of the periodic Fever syndrome with aphthous stomatitis, pharyngitis, and adenitis: a single center longitudinal study of 81 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692464" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-Term Outcome of Classic and Incomplete PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis) Syndrome after Tonsillectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27251674" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315168" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325152" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17013596" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Potential use of procalcitonin concentrations as a diagnostic marker of the PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33411886" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical Usefulness of Acute-Phase Markers in Distinguishing between PFAPA and Other Exudative Tonsillitis Causes: A Methodological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2797967" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271158" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Physicians' perspectives on the diagnosis and management of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31131563" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical features and new diagnostic criteria for the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31018962" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Classification criteria for autoinflammatory recurrent fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512793" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786432" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Differentiating PFAPA syndrome from monogenic periodic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502169" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Recurrent or episodic fever of unknown origin. Review of 45 cases and survey of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9880449" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Malignancies in children who initially present with rheumatic complaints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637003" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33067771" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Independent risk factors for resolution of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome within 4 years after the disease onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293478" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology research alliance (CARRA) PFAPA work group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293478" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology research alliance (CARRA) PFAPA work group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315860" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462461" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Colchicine prophylaxis for frequent periodic fever, aphthous stomatitis, pharyngitis and adenitis episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27068612" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Is colchicine an effective treatment in periodic fever, aphtous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966191" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Colchicine treatment in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966191" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Colchicine treatment in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023179" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : PFAPA syndrome in children evaluated for tonsillectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979131" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Periodic fever and pharyngitis in young children: a new disease for the otolaryngologist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12731633" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Update on treatment of Marshall's syndrome (PFAPA syndrome): report of five cases with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209129" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Role of Tonsillectomy in PFAPA Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283154" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of adenotonsillectomy in PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810475" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Utility of tonsillectomy in 2 patients with the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528401" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Outcome of tonsillectomy in selected patients with PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300374" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tonsillectomy in children with periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23069819" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term surgical outcomes of adenotonsillectomy for PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630321" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome: Relapse and Tonsillar Regrowth After Childhood Tonsillectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31886897" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719940" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A randomized, controlled trial of tonsillectomy in periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464029" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31603071" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis in Chinese adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858452" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Comparison of conventional and low dose steroid in the treatment of PFAPA syndrome: preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746456" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vitamin D levels and effects of vitamin D replacement in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870794" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vitamin D deficiency as a risk factor for PFAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711565" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Proposal for a new therapeutic high dosage of Pidotimod in children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: a randomized controlled study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
